

Substitute for form 1449A/B/PTO		JUN 30 2006		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number		10/801,648-Conf. #2232	
		Filing Date		March 17, 2004	
		First Named Inventor		Hsiang-Fu Kung	
		Art Unit		1633	
		Examiner Name		R. M. Kelly	
Sheet	1	of	1	Attorney Docket Number	V9661.0074

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RUK	CG2	Review "Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers"; Zhaohui Peng, Human Gene Therapy 16:1016-1027 (September 2005)	
RUK	CH2	"Generation of a High-Capacity Hybrid Vector: Packaging of Recombinant Adenoassociated Virus Replicative Intermediates in Adenovirus Capsids Overcomes the Limited Cloning Capacity of Adenoassociated Virus Vectors"; Manuel A. F.V. Goncalves, et al.; Virology 288, 236-246 (2001).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	8/22/06 8/22/06
-----------------------	---	--------------------	-------------------------------